Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

@article{Tefferi2011MyeloproliferativeNM,
  title={Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.},
  author={Ayalew Tefferi and William Vainchenker},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 5},
  pages={573-82}
}
To update oncologists on pathogenesis, contemporary diagnosis, risk stratification, and treatment strategies in BCR-ABL1-negative myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Recent literature was reviewed and interpreted in the context of the authors' own experience and expertise. Pathogenetic mechanisms in PV, ET, and PMF include stem cell-derived clonal myeloproliferation and secondary stromal changes in the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 123 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 103 references

A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea

  • S Verstovsek, F Passamonti, A Rambaldi
  • Blood 114:311,
  • 2009
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…